Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Quantbot Technologies LP

Quantbot Technologies LP lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 266.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 528 shares of the biopharmaceutical company’s stock after purchasing an additional 384 shares during the quarter. Quantbot Technologies LP’s holdings in Regeneron Pharmaceuticals were worth $376,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. TD Private Client Wealth LLC grew its holdings in Regeneron Pharmaceuticals by 9.6% during the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 15 shares during the period. DCF Advisers LLC lifted its position in shares of Regeneron Pharmaceuticals by 14.8% in the 4th quarter. DCF Advisers LLC now owns 8,900 shares of the biopharmaceutical company’s stock valued at $6,340,000 after acquiring an additional 1,150 shares in the last quarter. Douglass Winthrop Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 70.1% in the fourth quarter. Douglass Winthrop Advisors LLC now owns 364 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 150 shares during the period. Whittier Trust Co. grew its holdings in shares of Regeneron Pharmaceuticals by 12.8% during the fourth quarter. Whittier Trust Co. now owns 863 shares of the biopharmaceutical company’s stock valued at $615,000 after buying an additional 98 shares in the last quarter. Finally, Blueshift Asset Management LLC raised its position in Regeneron Pharmaceuticals by 284.4% during the fourth quarter. Blueshift Asset Management LLC now owns 1,303 shares of the biopharmaceutical company’s stock valued at $928,000 after buying an additional 964 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.2 %

REGN stock opened at $637.36 on Friday. The stock has a market capitalization of $69.68 billion, a price-to-earnings ratio of 16.65, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a 50-day moving average of $683.88 and a two-hundred day moving average of $800.34. Regeneron Pharmaceuticals, Inc. has a 52-week low of $629.02 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $11.86 EPS. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.55%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Bank of America reiterated an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Piper Sandler cut their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. Finally, Canaccord Genuity Group cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.